{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T22:17:16Z","timestamp":1794867436927,"version":"4.9.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,9]],"date-time":"2025-08-09T00:00:00Z","timestamp":1754697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,9]],"date-time":"2025-08-09T00:00:00Z","timestamp":1754697600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006955","name":"U.S. Department of Health & Human Services | NIH | Office of Extramural Research, National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006955","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The treatment and control of malaria in Africa is challenged by drug resistance. We characterized ex vivo susceptibilities to nine drugs of isolates collected from individuals presenting with uncomplicated falciparum malaria in eastern (2019-2024) and northern (2021-2024) Uganda and performed deep sequencing, with analysis of 80\n                    <jats:italic>Plasmodium falciparum<\/jats:italic>\n                    genes, to evaluate associations between susceptibilities and potential resistance markers for samples studied since 2016. For 1114 evaluated isolates, median half-maximal inhibitory concentrations (IC\n                    <jats:sub>50<\/jats:sub>\n                    s) were low-nanomolar for chloroquine, monodesethylamodiaquine, piperaquine, pyronaridine, lumefantrine, mefloquine, and DHA, but higher for quinine and pyrimethamine. Over time, susceptibilities improved for chloroquine, decreased for lumefantrine, mefloquine, and DHA, and were unchanged for other drugs. Changes in prevalences of known markers of altered drug susceptibility followed the same patterns. Genotypes associated with drug susceptibility were those previously identified for aminoquinolines and pyrimethamine. For lumefantrine, susceptibility was decreased with wild-type PfCRT K76T or PfMDR1 N86Y, mutant PfK13 C469Y or A675V, mutant PfCARL D611N, and other polymorphisms. For DHA, susceptibility was decreased with the PfK13 C469Y or A675V and PfMDR1 Y500N mutations. Decreasing activities of lumefantrine and DHA suggest potential loss of efficacies of leading regimens, although the clinical consequences of these changes are, to date, uncertain.\n                  <\/jats:p>","DOI":"10.1038\/s41467-025-62810-x","type":"journal-article","created":{"date-parts":[[2025,8,9]],"date-time":"2025-08-09T13:44:19Z","timestamp":1754747059000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Changes in susceptibility of Plasmodium falciparum to antimalarial drugs in Uganda over time: 2019\u20132024"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2712-2174","authenticated-orcid":false,"given":"Martin","family":"Okitwi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Orena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5933-1432","authenticated-orcid":false,"given":"Patrick K.","family":"Tumwebaze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Katairo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoweri","family":"Taremwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oswald","family":"Byaruhanga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Tukwasibwe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel L.","family":"Nsobya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Legac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6899-8204","authenticated-orcid":false,"given":"Jeffrey A.","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland A.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9984-8030","authenticated-orcid":false,"given":"Melissa D.","family":"Conrad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7953-7622","authenticated-orcid":false,"given":"Philip J.","family":"Rosenthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,9]]},"reference":[{"key":"62810_CR1","unstructured":"World Health Organization. WHO Guidelines for Malaria. (World Health Organization, 2023)."},{"key":"62810_CR2","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/s41573-024-00933-4","volume":"23","author":"M Duffey","year":"2024","unstructured":"Duffey, M. et al. Combating antimicrobial resistance in malaria, HIV and tuberculosis. Nat. Rev. Drug Discov. 23, 461\u2013479 (2024).","journal-title":"Nat. Rev. Drug Discov."},{"key":"62810_CR3","doi-asserted-by":"publisher","first-page":"e0010924","DOI":"10.1128\/cmr.00109-24","volume":"37","author":"NJ White","year":"2024","unstructured":"White, N. J. & Chotivanich, K. Artemisinin-resistant malaria. Clin. Microbiol Rev. 37, e0010924 (2024).","journal-title":"Clin. Microbiol Rev."},{"key":"62810_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-022-04115-8","volume":"21","author":"CV Plowe","year":"2022","unstructured":"Plowe, C. V. Malaria chemoprevention and drug resistance: a review of the literature and policy implications. Malar. J. 21, 104 (2022).","journal-title":"Malar. J."},{"key":"62810_CR5","doi-asserted-by":"publisher","first-page":"e338","DOI":"10.1016\/S1473-3099(19)30261-0","volume":"19","author":"MD Conrad","year":"2019","unstructured":"Conrad, M. D. & Rosenthal, P. J. Antimalarial drug resistance in Africa: the calm before the storm? Lancet Infect. Dis. 19, e338\u2013e351 (2019).","journal-title":"Lancet Infect. Dis."},{"key":"62810_CR6","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.chom.2019.06.001","volume":"26","author":"LS Ross","year":"2019","unstructured":"Ross, L. S. & Fidock, D. A. Elucidating mechanisms of drug-resistant Plasmodium falciparum. Cell Host Microbe 26, 35\u201347 (2019).","journal-title":"Cell Host Microbe"},{"key":"62810_CR7","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1146\/annurev-micro-020518-115546","volume":"74","author":"KJ Wicht","year":"2020","unstructured":"Wicht, K. J., Mok, S. & Fidock, D. A. Molecular mechanisms of drug resistance in Plasmodium falciparum malaria. Annu Rev. Microbiol 74, 431\u2013454 (2020).","journal-title":"Annu Rev. Microbiol"},{"key":"62810_CR8","doi-asserted-by":"publisher","first-page":"e01516","DOI":"10.1128\/AAC.01516-17","volume":"61","author":"SA Rasmussen","year":"2017","unstructured":"Rasmussen, S. A. et al. Changing antimalarial drug sensitivities in Uganda. Antimicrob. Agents Chemother. 61, e01516\u2013e01517 (2017).","journal-title":"Antimicrob. Agents Chemother."},{"key":"62810_CR9","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S1473-3099(23)00502-9","volume":"24","author":"C Florimond","year":"2024","unstructured":"Florimond, C. et al. Impact of piperaquine resistance in Plasmodium falciparum on malaria treatment effectiveness in The Guianas: a descriptive epidemiological study. Lancet Infect. Dis. 24, 161\u2013171 (2024).","journal-title":"Lancet Infect. Dis."},{"key":"62810_CR10","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1097\/QCO.0000000000000766","volume":"34","author":"M Dhorda","year":"2021","unstructured":"Dhorda, M., Amaratunga, C. & Dondorp, A. M. Artemisinin and multidrug-resistant Plasmodium falciparum - a threat for malaria control and elimination. Curr. Opin. Infect. Dis. 34, 432\u2013439 (2021).","journal-title":"Curr. Opin. Infect. Dis."},{"key":"62810_CR11","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/s41579-024-01008-2","volume":"22","author":"PJ Rosenthal","year":"2024","unstructured":"Rosenthal, P. J., Asua, V. & Conrad, M. D. Emergence, transmission dynamics and mechanisms of artemisinin partial resistance in malaria parasites in Africa. Nat. Rev. Microbiol. 22, 373\u2013384 (2024).","journal-title":"Nat. Rev. Microbiol."},{"key":"62810_CR12","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1038\/s41591-020-1005-2","volume":"26","author":"A Uwimana","year":"2020","unstructured":"Uwimana, A. et al. Emergence and clonal expansion of in vitro artemisinin-resistant Plasmodium falciparum kelch13 R561H mutant parasites in Rwanda. Nat. Med. 26, 1602\u20131608 (2020).","journal-title":"Nat. Med."},{"key":"62810_CR13","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/S1473-3099(21)00142-0","volume":"21","author":"A Uwimana","year":"2021","unstructured":"Uwimana, A. et al. Association of Plasmodium falciparum kelch13 R561H genotypes with delayed parasite clearance in Rwanda: an open-label, single-arm, multicentre, therapeutic efficacy study. Lancet Infect. Dis. 21, 1120\u20131128 (2021).","journal-title":"Lancet Infect. Dis."},{"key":"62810_CR14","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1016\/S1473-3099(24)00362-1","volume":"24","author":"DS Ishengoma","year":"2024","unstructured":"Ishengoma, D. S. et al. Evidence of artemisinin partial resistance in northwestern Tanzania: clinical and molecular markers of resistance. Lancet Infect. Dis. 24, 1225\u20131233 (2024).","journal-title":"Lancet Infect. Dis."},{"key":"62810_CR15","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1056\/NEJMoa2211803","volume":"389","author":"MD Conrad","year":"2023","unstructured":"Conrad, M. D. et al. Evolution of partial resistance to artemisinins in malaria parasites in Uganda. N. Engl. J. Med. 389, 722\u2013732 (2023).","journal-title":"N. Engl. J. Med."},{"key":"62810_CR16","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1056\/NEJMoa2101746","volume":"385","author":"B Balikagala","year":"2021","unstructured":"Balikagala, B. et al. Evidence of artemisinin-resistant malaria in Africa. N. Engl. J. Med. 385, 1163\u20131171 (2021).","journal-title":"N. Engl. J. Med."},{"key":"62810_CR17","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1056\/NEJMoa2210956","volume":"389","author":"S Mihreteab","year":"2023","unstructured":"Mihreteab, S. et al. Increasing prevalence of artemisinin-resistant HRP2-negative malaria in Eritrea. N. Engl. J. Med. 389, 1191\u20131202 (2023).","journal-title":"N. Engl. J. Med."},{"key":"62810_CR18","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1038\/s41564-023-01461-4","volume":"8","author":"AA Fola","year":"2023","unstructured":"Fola, A. A. et al. Plasmodium falciparum resistant to artemisinin and diagnostics have emerged in Ethiopia. Nat. Microbiol. 8, 1911\u20131919 (2023).","journal-title":"Nat. Microbiol."},{"key":"62810_CR19","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1124\/pr.57.1.4","volume":"57","author":"A Gregson","year":"2005","unstructured":"Gregson, A. & Plowe, C. V. Mechanisms of resistance of malaria parasites to antifolates. Pharm. Rev. 57, 117\u2013145 (2005).","journal-title":"Pharm. Rev."},{"key":"62810_CR20","doi-asserted-by":"publisher","first-page":"e4569","DOI":"10.1371\/journal.pone.0004569","volume":"4","author":"S Gesase","year":"2009","unstructured":"Gesase, S. et al. High resistance of Plasmodium falciparum to sulphadoxine\/pyrimethamine in northern Tanzania and the emergence of dhps resistance mutation at Codon 581. PLoS One 4, e4569 (2009).","journal-title":"PLoS One"},{"key":"62810_CR21","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1093\/infdis\/jiaa687","volume":"223","author":"V Asua","year":"2021","unstructured":"Asua, V. et al. Changing prevalence of potential mediators of aminoquinoline, antifolate, and artemisinin resistance across Uganda. J. Infect. Dis. 223, 985\u2013994 (2021).","journal-title":"J. Infect. Dis."},{"key":"62810_CR22","doi-asserted-by":"publisher","first-page":"3018","DOI":"10.1128\/AAC.05141-14","volume":"59","author":"P Tumwebaze","year":"2015","unstructured":"Tumwebaze, P. et al. Impact of antimalarial treatment and chemoprevention on the drug sensitivity of malaria parasites isolated from Ugandan children. Antimicrob. Agents Chemother. 59, 3018\u20133030 (2015).","journal-title":"Antimicrob. Agents Chemother."},{"key":"62810_CR23","doi-asserted-by":"publisher","first-page":"e441","DOI":"10.1016\/S2666-5247(21)00085-9","volume":"2","author":"PK Tumwebaze","year":"2021","unstructured":"Tumwebaze, P. K. et al. Drug susceptibility of Plasmodium falciparum in eastern Uganda: a longitudinal phenotypic and genotypic study. Lancet Microbe 2, e441\u2013e449 (2021).","journal-title":"Lancet Microbe"},{"key":"62810_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33873-x","volume":"13","author":"PK Tumwebaze","year":"2022","unstructured":"Tumwebaze, P. K. et al. Decreased susceptibility of Plasmodium falciparum to both dihydroartemisinin and lumefantrine in northern Uganda. Nat. Commun. 13, 6353 (2022).","journal-title":"Nat. Commun."},{"key":"62810_CR25","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1093\/infdis\/jiv551","volume":"213","author":"A Yeka","year":"2016","unstructured":"Yeka, A. et al. Artesunate\/amodiaquine versus artemether\/lumefantrine for the treatment of uncomplicated malaria in Uganda: a randomized trial. J. Infect. Dis. 213, 1134\u20131142 (2016).","journal-title":"J. Infect. Dis."},{"key":"62810_CR26","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1093\/infdis\/jiy637","volume":"219","author":"A Yeka","year":"2019","unstructured":"Yeka, A. et al. Comparative efficacy of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated malaria in Ugandan children. J. Infect. Dis. 219, 1112\u20131120 (2019).","journal-title":"J. Infect. Dis."},{"key":"62810_CR27","doi-asserted-by":"publisher","first-page":"857","DOI":"10.4269\/ajtmh.21-0797","volume":"105","author":"PJ Rosenthal","year":"2021","unstructured":"Rosenthal, P. J. Are artemisinin-based combination therapies for malaria beginning to fail in Africa?. Am. J. Trop. Med. Hyg. 105, 857\u2013858 (2021).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"62810_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-021-04021-5","volume":"20","author":"C Ebong","year":"2021","unstructured":"Ebong, C. et al. Efficacy and safety of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria and prevalence of molecular markers associated with artemisinin and partner drug resistance in Uganda. Malar. J. 20, 484 (2021).","journal-title":"Malar. J."},{"key":"62810_CR29","doi-asserted-by":"publisher","first-page":"5061","DOI":"10.1128\/AAC.00921-15","volume":"59","author":"RA Cooper","year":"2015","unstructured":"Cooper, R. A. et al. Lack of artemisinin resistance in Plasmodium falciparum in Uganda based on parasitological and molecular assays. Antimicrob. Agents Chemother. 59, 5061\u20135064 (2015).","journal-title":"Antimicrob. Agents Chemother."},{"key":"62810_CR30","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/S1473-3099(13)70252-4","volume":"13","author":"B Witkowski","year":"2013","unstructured":"Witkowski, B. et al. Novel phenotypic assays for the detection of artemisinin-resistant Plasmodium falciparum malaria in Cambodia: in-vitro and ex-vivo drug-response studies. Lancet Infect. Dis. 13, 1043\u20131049 (2013).","journal-title":"Lancet Infect. Dis."},{"key":"62810_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-021-03823-x","volume":"20","author":"M Duvalsaint","year":"2021","unstructured":"Duvalsaint, M. et al. Balanced impacts of fitness and drug pressure on the evolution of PfMDR1 polymorphisms in Plasmodium falciparum. Malar. J. 20, 292 (2021).","journal-title":"Malar. J."},{"key":"62810_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05652-0","volume":"9","author":"LS Ross","year":"2018","unstructured":"Ross, L. S. et al. Emerging Southeast Asian PfCRT mutations confer Plasmodium falciparum resistance to the first-line antimalarial piperaquine. Nat. Commun. 9, 3314 (2018).","journal-title":"Nat. Commun."},{"key":"62810_CR33","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.4269\/ajtmh.2010.10-0339","volume":"83","author":"M Mungthin","year":"2010","unstructured":"Mungthin, M. et al. Association between the pfmdr1 gene and in vitro artemether and lumefantrine sensitivity in Thai isolates of Plasmodium falciparum. Am. J. Trop. Med. Hyg. 83, 1005\u20131009 (2010).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"62810_CR34","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S1473-3099(16)30409-1","volume":"17","author":"R Amato","year":"2017","unstructured":"Amato, R. et al. Genetic markers associated with dihydroartemisinin-piperaquine failure in Plasmodium falciparum malaria in Cambodia: a genotype-phenotype association study. Lancet Infect. Dis. 17, 164\u2013173 (2017).","journal-title":"Lancet Infect. Dis."},{"key":"62810_CR35","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1086\/500951","volume":"193","author":"D Francis","year":"2006","unstructured":"Francis, D. et al. Geographic differences in antimalarial drug efficacy in Uganda are explained by differences in endemicity and not by known molecular markers of drug resistance. J. Infect. Dis. 193, 978\u2013986 (2006).","journal-title":"J. Infect. Dis."},{"key":"62810_CR36","doi-asserted-by":"crossref","unstructured":"Dimbu P. R. et al. Continued low efficacy of artemether-lumefantrine in Angola in 2019. Antimicrob Agents Chemother 65, e01949 (2021).","DOI":"10.1128\/AAC.01949-20"},{"key":"62810_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-021-03585-6","volume":"20","author":"A Gansane","year":"2021","unstructured":"Gansane, A. et al. Anti-malarial efficacy and resistance monitoring of artemether-lumefantrine and dihydroartemisinin-piperaquine shows inadequate efficacy in children in Burkina Faso, 2017-2018. Malar. J. 20, 48 (2021).","journal-title":"Malar. J."},{"key":"62810_CR38","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.4269\/ajtmh.21-0214","volume":"105","author":"LF Moriarty","year":"2021","unstructured":"Moriarty, L. F. et al. Therapeutic efficacy of artemisinin-based combination therapies in Democratic Republic of the Congo and investigation of molecular markers of antimalarial resistance. Am. J. Trop. Med Hyg. 105, 1067\u20131075 (2021).","journal-title":"Am. J. Trop. Med Hyg."},{"key":"62810_CR39","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1093\/infdis\/jiae425","volume":"231","author":"JE Laury","year":"2025","unstructured":"Laury, J. E. et al. Efficacy and safety of artemether-lumefantrine against uncomplicated falciparum malaria infection in Tanzania, 2022: a single-arm clinical trial. J. Infect. Dis. 231, 251\u2013259 (2025).","journal-title":"J. Infect. Dis."},{"key":"62810_CR40","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.4269\/ajtmh.20-1481","volume":"104","author":"MM Plucinski","year":"2021","unstructured":"Plucinski, M. M. et al. Variation in calculating and reporting antimalarial efficacy against Plasmodium falciparum in sub-Saharan Africa: a systematic review of published reports. Am. J. Trop. Med Hyg. 104, 1820\u20131829 (2021).","journal-title":"Am. J. Trop. Med Hyg."},{"key":"62810_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-88892-7","volume":"15","author":"A Mwesigwa","year":"2025","unstructured":"Mwesigwa, A. et al. Assessment of different genotyping markers and algorithms for distinguishing Plasmodium falciparum recrudescence from reinfection in Uganda. Sci. Rep. 15, 4375 (2025).","journal-title":"Sci. Rep."},{"key":"62810_CR42","doi-asserted-by":"publisher","first-page":"100914","DOI":"10.1016\/S2666-5247(24)00153-8","volume":"5","author":"A Schnoz","year":"2024","unstructured":"Schnoz, A. et al. Genotyping methods to distinguish Plasmodium falciparum recrudescence from new infection for the assessment of antimalarial drug efficacy: an observational, single-centre, comparison study. Lancet Microbe 5, 100914 (2024).","journal-title":"Lancet Microbe"},{"key":"62810_CR43","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1093\/cid\/ciad724","volume":"78","author":"DA van Schalkwyk","year":"2024","unstructured":"van Schalkwyk, D. A. et al. Treatment failure in a UK malaria patient harboring genetically variant Plasmodium falciparum from Uganda with reduced in vitro susceptibility to artemisinin and lumefantrine. Clin. Infect. Dis. 78, 445\u2013452 (2024).","journal-title":"Clin. Infect. Dis."},{"key":"62810_CR44","doi-asserted-by":"publisher","first-page":"taad165","DOI":"10.1093\/jtm\/taad165","volume":"31","author":"J Pierreux","year":"2024","unstructured":"Pierreux, J. et al. Failure of artemether-lumefantrine therapy in travellers returning to Belgium with Plasmodium falciparum malaria: an observational case series with genomic analysis. J. Travel Med. 31, taad165 (2024).","journal-title":"J. Travel Med."},{"key":"62810_CR45","doi-asserted-by":"publisher","first-page":"taaf013","DOI":"10.1093\/jtm\/taaf013","volume":"32","author":"R Oliveira","year":"2025","unstructured":"Oliveira, R. et al. Artemether-lumefantrine resistant falciparum malaria imported from Uganda. J. Travel Med. 32, taaf013 (2025).","journal-title":"J. Travel Med."},{"key":"62810_CR46","doi-asserted-by":"publisher","first-page":"e1001689","DOI":"10.1371\/journal.pmed.1001689","volume":"11","author":"V Bigira","year":"2014","unstructured":"Bigira, V. et al. Protective efficacy and safety of three antimalarial regimens for the prevention of malaria in young Ugandan children: a randomized controlled trial. PLoS Med. 11, e1001689 (2014).","journal-title":"PLoS Med."},{"key":"62810_CR47","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/S0140-6736(24)02706-5","volume":"405","author":"R Martinez-Vega","year":"2025","unstructured":"Martinez-Vega, R. et al. Regional action needed to halt antimalarial drug resistance in Africa. Lancet 405, 7\u201310 (2025).","journal-title":"Lancet"},{"key":"62810_CR48","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1177\/108705719900400206","volume":"4","author":"JH Zhang","year":"1999","unstructured":"Zhang, J. H., Chung, T. D. & Oldenburg, K. R. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screen 4, 67\u201373 (1999).","journal-title":"J. Biomol. Screen"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-62810-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-62810-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-62810-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T15:53:50Z","timestamp":1757346830000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-62810-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,9]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["62810"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-62810-x","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,9]]},"assertion":[{"value":"24 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7353"}}